Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies

Bibliography

• Rowley JD. Chromosomal translocations: revisited yet again. Blood 2008;112(6):2183-9
   PubMed Web of Science ®Google Scholar
• Moving AHEAD with an international human epigenome project. Nature 2008;454(7205):711-15
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-54
   PubMed Web of Science ®Google Scholar
• Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010;10(1):23-36
   PubMed Web of Science ®Google Scholar
• Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007;14(11):1008-16
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009;15(12):3918-26
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell A, Abraham S, Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11(10):3604-8
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27(23):3842-8
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5(1):37-50
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15(12):3958-69
   PubMed Web of Science ®Google Scholar
• Ueda H, Manda T, Matsumoto S, FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994;47(3):315-23
   PubMed Web of Science ®Google Scholar
• Ueda H, Nakajima H, Hori Y, Action of FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994;58(9):1579-83
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kim YB, Terano H, FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241(1):126-33
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62(17):4916-21
   PubMed Web of Science ®Google Scholar
• Aron JL, Parthun MR, Marcucci G, Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102(2):652-8
   PubMed Web of Science ®Google Scholar
• Klisovic MI, Maghraby EA, Parthun MR, Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 2003;17(2):350-8
   PubMed Web of Science ®Google Scholar
• Yang G, Thompson MA, Brandt SJ, Hiebert SW. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007;26(1):91-101
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8(3):718-28
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J, A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2(6):325-32
   PubMedGoogle Scholar
• Woo S, Gardner ER, Chen X, Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009;15(4):1496-503
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105(3):959-67
   PubMed Web of Science ®Google Scholar
• Fouladi M, Furman WL, Chin T, Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006;24(22):3678-85
   PubMed Web of Science ®Google Scholar
• Shiraga T, Tozuka Z, Ishimura R, Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005;28(1):124-9
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148(2):256-67
   Google Scholar
• Xiao JJ, Huang Y, Dai Z, Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 2005;314(1):467-75
   PubMed Web of Science ®Google Scholar
• Robey RW, Zhan Z, Piekarz RL, Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006;12(5):1547-55
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D, Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008;14(21):7095-101
   PubMed Web of Science ®Google Scholar
• Hauswald S, Duque-Afonso J, Wagner MM, Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009;15(11):3705-15
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Foraker AB, Swaan PW, Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther 2005;313(1):268-76
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-Cell Lymphoma. J Clin Oncol 2010;28(29):4485-91
   Google Scholar
• Shah MH, Binkley P, Chan K, Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12(12):3762-73
   PubMed Web of Science ®Google Scholar
• Molife R, Fong P, Scurr M, HDAC inhibitors and cardiac safety. Clin Cancer Res 2007;13(3):1068, author reply 1068-9
   PubMed Web of Science ®Google Scholar
• Cabell C, Bates S, Piekarz R, Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin [abstract]. Blood 2009;114:3709
   Web of Science ®Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood 2009;114(20):4337-53
   PubMed Web of Science ®Google Scholar
• van Doorn R, Van Haselen CW, van Voorst Vader PC, Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136(4):504-10
   PubMedGoogle Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139(7):857-66
   PubMedGoogle Scholar
• Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40(3):418-25
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98(9):2865-8
   PubMed Web of Science ®Google Scholar
• Demierre M, Whittaker S, Kim Y, Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous t-cell lymphoma (CTCL). [abstract] J Clin Oncol 2009;27:15s
   Web of Science ®Google Scholar
• Foss FM. Enhancing existing approaches to peripheral T-cell lymphoma. Semin Hematol 2010;47(Suppl 1):S8-10
   Google Scholar
• O'Connor OA, Horwitz S, Hamlin P, Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009;27(26):4357-64
   PubMed Web of Science ®Google Scholar
• Piekarz R, Wright J, Frye R, Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). [Abstract]. Blood 2009;114:1657
   Web of Science ®Google Scholar
• Klimek VM, Fircanis S, Maslak P, Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14(3):826-32
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Mark T, Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer Sep 22 2010. [Epub ahead of print]
   Google Scholar
• Kikuchi J, Wada T, Shimizu R, Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010;116(3):406-17
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Quach H, Yuen K, High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a Phase I/II Clinical Trial (Abstract). Blood 2008;112:3698a
   Web of Science ®Google Scholar
• Dai Y, Chen S, Kramer LB, Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008;14(2):549-58
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Scotto L, Marchi E, Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010;16(2):554-65
   PubMed Web of Science ®Google Scholar
• Shimizu R, Kikuchi J, Wada T, HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010;24(10):1760-8
   Google Scholar
• Olsen EA, Kim YH, Kuzel TM, Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-1252
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Dedes I, Imesch P, Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009;20(5):321-33
   PubMed Web of Science ®Google Scholar
• Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280(2):125-33
   PubMed Web of Science ®Google Scholar